REG - AstraZeneca PLC - Director/PDMR Shareholding
RNS Number : 6032NAstraZeneca PLC30 September 202130 September 2021 16:00 BST
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 30 September 2021, it was notified by Pascal Soriot, Chief Executive Officer, that, on 30 September 2021, Mr Soriot ceased to be beneficially interested in 231,922 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Pascal Soriot
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
AstraZeneca PLC
b)
LEI
PY6ZZQWO2IZFZC3IOL08
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b)
Nature of the transaction
Gift of shares to family members for nil consideration
c)
Price(s) and volume(s)
Price(s)
Volume(s)
0
231,922
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
30 September 2021
f)
Place of the transaction
Outside a trading venue
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company SecretaryAstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHURRSRAAUKOAR
Recent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Calquence combination improved PFS in 1L MCL
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - Stock Exch Notice - Admission to ISM - 17/04/2024
AnnouncementREG - AstraZeneca PLC - Result of AGM
Announcement